Dehydroepiandrosterone stimulates nerve growth factor and brain derived neurotrophic factor in cortical neurons by Rahmani, A. et al.
Hindawi Publishing Corporation
Advances in Pharmacological Sciences
Volume 2013, Article ID 506191, 7 pages
http://dx.doi.org/10.1155/2013/506191
Research Article
Dehydroepiandrosterone Stimulates Nerve Growth Factor and
Brain Derived Neurotrophic Factor in Cortical Neurons
Anahita Rahmani,1 Alireza Shoae-Hassani,1,2 Peyman Keyhanvar,3
Danial Kheradmand,4 and Amir Darbandi-Azar3
1 Stem Cell and Tissue Engineering Department, Research Center for Science and Technology in Medicine (RCSTiM),
Tehran University of Medical Sciences, Tehran 19988-96953, Iran
2 Applied Cell Sciences Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences,
Tehran 19988-96953, Iran
3 Rajaie Cardiovascular, Medical and Research Centre, Iran University of Medical Sciences, Tehran 19969-14151, Iran
4 Faculty of Medicine, Islamic Azad University of Mashhad, Mashhad 91779-48564, Iran
Correspondence should be addressed to Amir Darbandi-Azar; nanobiotechnology@ymail.com
Received 13 August 2013; Revised 15 October 2013; Accepted 15 October 2013
Academic Editor: Karim A. Alkadhi
Copyright © 2013 Anahita Rahmani et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Due to the increasing cases of neurodegenerative diseases in recent years, the eventual goal of nerve repair is very important.
One approach for achieving a neuronal cell induction is by regenerative pharmacology. Nerve growth factor (NGF) and brain
derived neurotrophic factor (BDNF) are neurotrophins that play roles in neuronal development, differentiation, and protection.
On the other hand, dehydroepiandrosterone (DHEA) is a neurosteroid which has multiple actions in the nervous system. DHEA
could be an important agent in regenerative pharmacology for neuronal differentiation during tissue regeneration. In this study,
we investigated the possible role of DHEA to modulate NGF and BDNF production. The in vivo level of neurotrophins expression
was demonstrated by ELISA in rat harvested brain cortex. Also neurotrophins expression after DHEA treatment was revealed by
the increased neurite extension, immunostaining, and BrdU labeling in rats. Anti-NGF and anti-BDNF antibodies were used as
suppressive agents on neurogenesis. The results showed that NGF and BDNF are overproduced after DHEA treatment but there is
not any overexpression for NT-3 and NT-4. Also DHEA increased neurite extension and neural cell proliferation significantly.
Overall, DHEA might induce NGF and BDNF neurotrophins overproduction in cortical neurons which promotes neural cell
protection, survival, and proliferation.
1. Introduction
The central nervous system (CNS) is composed of an orches-
trated control of cell proliferation, motility andmaturation of
neuronal and glial cells, axonal growth, neurite outgrowth,
and the design of synapses. Neurotrophins are originally
identified as important peptides involved in the development
of nervous system and could determine neuronal differen-
tiation phenotype. The neurotrophins that influence neu-
ral development include nerve growth factor (NGF), brain
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3),
NT-4/5, and neurotrophin-6 (NT-6) [1, 2]. Nerve growth fac-
tor (NGF) is themost important target-derived trophic factor
for basal forebrain cholinergic neurons (BFCNs) [3]. These
are small proteins, which share more than 50% sequence
homology. These factors could enhance survival, prolifer-
ation, and differentiation of postmitotic neurons [4]. It is
known that they could increase in neuronal numbers and
neurite outgrowth [5]. So it is important to find molecules
that promote overproduction of the neurotrophins. In this
study, we focused to understand the induction of NGF and
BDNF through dehydroepiandrosterone (DHEA) as a phar-
macological agent.
DHEA is an adrenal, glial, and neuronal derived steroid.
Although DHEA is produced by the human adrenal, it is not
produced by the rodent adrenal. It has multiple actions in the
nervous system but no specific receptor has been reported for
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this neurosteroid. DHEA could be an important agent in neu-
ronal differentiation during development [6] or could provide
a microenvironment for stem cells neurogenesis [7]. DHEA
is present in very low concentrations in the blood of rats;
however, the rodent brainmay be able tomake it from its pre-
cursor pregnenolone [6]. In adults, DHEA could act as anti-
corticosteroid molecule on in vitro cultures of neurons [8]. It
protects hippocampal cells from oxidative stress [9] and
antagonizes the neurotoxic effects of corticosterones in pri-
mary cultures of neurons [10].
The successful regeneration of the neurons is dependent
on the cells survival and their progenitors proliferation [11].
From the point that DHEA (its sulfate form; DHEAS) is the
most frequent neurosteroid in the human body, we hypothe-
sized that DHEAmay influence the NGF and BDNF produc-
tion to induce neurogenesis and/or neuronal survival.
2. Materials and Methods
2.1. In Vivo Studies
2.1.1. Animals Handling. This study was carried out in accor-
dance with the Guide for the Care and Use of Laboratory
Animals of the Tehran University of Medical Sciences. The
protocol was approved by the Institutional Animal Care and
Use Committee at the Research Center for Science and Tech-
nology in Medicine, Tehran University of Medical Sciences.
Fifty-four male Wistar rats (aged between 15 and 45 days)
were purchased from Pasteur institute, Tehran, Iran.The ani-
mals were housed in the polypropylene cages, three per cage,
in a controlled temperature (22∘C), under a 12 h light: dark
cycle. Food and water were available ad libitum. We divided
the animals into 6 treatment groups (three groups for in
vivo studies and three groups just for extraction of cortical
neurons); each contained 9members. For in vivo studies, each
group was subjected for DHEA treatment, BrdU labeling,
DHEA measurement, and neurotrophins quantitation in
triplicate.
2.1.2. Drug Treatment. DHEAwas used in the concentrations
of 8mg/kg daily subcutaneously under anesthesia for 2weeks.
The treatment dose was chosen according to several studies
conducted on adult rats. This dose is in the middle of the
range found effective in many studies and that might show
oversensitivity to the higher doses [12–15].
2.1.3. BromodeoxyuridineAssay. Bromodeoxyuridine (BrdU)
incorporation was assessed as described by Pechnick et al., in
2008 [16].The rats were injected every 2 h with BrdU (Sigma-
Aldridge, 100mg/kg/i.p.) for a total of three injections and
then sacrificed 24 h after the first BrdU injection. The entire
cortex of the brainwas cut into sections and processed using a
BrdUDetection Kit (Roche Applied Biosystems, USA). Every
third section (over 36 sections) was counted and the sumwas
multiplied by 3 to estimate the total number of BrdU-positive
cells in the cortex region.
2.1.4. DHEA Determination. DHEA basal level in brain was
measured using Radioimmunoassay (RIA) kit (Diagnostic
Systems Laboratories, USA). OnemL of cortex region homo-
genates was extracted with 1mL di-ethyl-ether, centrifuged at
300 g for 10min, and kept for about 15min at −70∘C to freeze.
The ether phase was decanted into a new glass tube, evapo-
rated till dryness, and dissolved in 120 𝜇L of standard zero of
the RIA kit. One hundred 𝜇L of the solution was used for the
determination of DHEA [17]. Cross-reactivity with other
steroids is <0.2%. Results are presented in pmol/mg.
2.1.5. Neurotrophic Factors Determination. The levels of NGF,
BDNF, NT-3, and NT-4 were determined using Emax Immu-
noAssay System (Promega, USA) as previously described
[18]. Briefly the brain cortex from Wistar rats were collected
in homogenization buffer (1 : 10 diluted, 0.4M NaCl, 5mM
EDTA, 0.5% bovine serum albumin (BSA), 1mM phenyl-
methylsulfonyl fluoride (PMSF), and 0.1% Triton X-100) and
sonicated for 15 s in an ice bath. After the supernatant was
collected in a new tube, the pellet was carefully washed twice
with phosphate buffered saline (PBS) and resuspended in cold
homogenization buffer. Each fraction was assayed in parallel
ELISA Emax ImmunoAssay System (Promega, USA).
2.2. In Vitro Studies
2.2.1. Isolation and Culture of Cortical Neurons. Cortical neu-
rons were isolated from cerebral cortex of rats. Isolated cere-
bral cortex was suspended in neurobasal medium (GIBCO,
USA) containing B-27 supplement (Invitrogen, USA). The
suspension was placed on poly-D-lysine coated plates. The
cultures were kept in the 90% humidity and 10% CO
2
atmo-
sphere at 37∘C for 14 days and media were half-replaced with
fresh media every 3 days.
2.2.2. DHEA Treatment. DHEA was used as a series of con-
centration (10−4–10−8mol/mL) in neurobasal medium. Cor-
tical neurons were isolated from cerebral cortex of rats sus-
pended in this treated medium.The cultures were kept in the
90%humidity and 10%CO
2
atmosphere at 37∘C for 2weeks as
described above. Anti-NGF and anti-BDNF antibodies (each
2 𝜇g/mL, Santa Cruz, CA, USA) were used to block NGF and
BDNF action from DHEA treated neurons. A group from
each treatmentwas kept for onemonth (30 days) to survey the
cell survival after treatments. MTT assay was used to deter-
mine the survival rate of cells before and after treatment.
2.2.3. ELISA. The amount of released neurotrophins was
quantified from medium of treated neuron (Promega kit,
USA). ELISAwas performed according to themanufacturer’s
manual. Briefly, the wells of plates were coated with anti-
NGF/anti-BDNF mAb diluted with carbonate coating buffer
at 4∘C for 24 h. After 1 h blockade with blocking buffer, the
plates were incubated with standard and culture medium
sample for 2 h followed by incubation with anti-rat
BDNF/anti-rat NGF polyclonal Ab. After 1 h incubation
of Anti-Ig HRP conjugate, the reaction was developed with
tetra-methyl-benzidine and the absorbance was read at
450 nm with a plate reader after stopping the reaction with
1N HCl.
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Figure 1: Mean basal levels of DHEA of 15–30–45-day old Wistar rats (a). Mean basal levels of NGF, BDNF, NT-3, and NT-4 neurotrophins
in the brain cortex of 30-day old Wistar rats and Mean levels of neurotrophins after DHEA treatment in the brain cortex of Wistar rats. A
comparison between basal levels of NGF, BDNF, NT-3, and NT-4 neurotrophines before and after DHEA treatment in the brain cortex of
Wistar rats. The levels of NGF, BDNF, NT-3, and NT-4 neurotrophines were measured using ELISA (b). In each part, the data are obtained
from nine animals.
2.2.4. Immunocytochemistry Assay. Isolated cortical neurons
from treated rats in all groups were plated on 24-well
plates (Greiner, Germany). These cells were fixed in 4%
paraformaldehyde (PFA in PBS) and washed in PBS.The cells
were then incubated in 2MHCl for 30min at 37∘C.Then they
was neutralized with 0.1M NaOH and washed several times
in PBS. Fixed cells were blocked in 5% bovine serum albumin
(BSA) with 0.3% Triton X-100 and incubated with anti-
MAP-2 (microtubule associated protein 2) antibody (mono-
clonal 1 : 1000, Chemicon). After incubation with the primary
antibodies, FITC conjugated secondary antibody (1 : 500,
AbCam, UK) was used to visualize the signal with Ceti
immunofluorescence microscopy [19].
2.2.5. Statistical Analysis. Data are presented as means ± SD.
DHEA and BDNF basal levels were analyzed by independent
𝑡-tests. Significance of differences was tested by ANOVA.
Differences were considered significant at values of 𝑃 ≤ 0.05.
3. Results
3.1. DHEAStimulatedNGFandBDNFExpression andRelease.
The basal levels of DHEA (Figure 1(a)), NGF, and BDNF in
the brain cortex are presented in Figure 1(b). ELISA results
showed that treatment of DHEA increased NGF and BDNF
levels, 7- and 5-fold (Figure 1(b)) compared with control,
respectively (Figure 1(b)). The levels of NT-3 and NT-4 did
not influence after DHEA treatment (Figure 1(b)).
3.2. DHEA Stimulated Cortical Neurons Proliferation. Rats
treated with DHEA daily showed increase in neural cells
proliferation. BrdU-labeled neurons were found in all treat-
ment groups (Figure 2(a)). Analysis by one-way ANOVA
also showed a significant effect of treatment on neuroge-
nesis. DHEA increased the number of BrdU-labeled cells
(Figure 2(b)). Antineurotrophin antibodies were decreased
in the BrdU-labeled cells. To test the involvement of NGF and
BDNF in the proliferation effect of DHEA, we used their anti-
bodies to inactivate these neurotrophins. Anti-NGF and anti-
BDNF decreased the neurogenesis even more than DHEA
nontreated groups. Among these 2 neurotrophic factors the
role of NGF was more important than BDNF (Figure 2(b)).
The number of newly formed cells was higher in the rats just
received DHEA. Also there were more neuronal cells in the
group received anti-BDNF in comparisonwith those received
anti-NGF. However there must be a relationship between
these neurotrophins amount and function.
3.3. DHEA Induces Neurite Outgrowth in Cultured Rat Neu-
rons. Considering the roles of NGF and BDNF in neurons,
we investigated the role of DHEA on the neurite outgrowth
in rat cortical neurons. The cultured cortical neurons were
treated with DHEA and visualized by a neural cell marker,
MAP-2 (Figure 3(a)). DHEA increased the average number
of neurite branches extending from a single neuron as well as
the length of individual neurite (Figure 3(b)). Treatment with
anti-NGF inhibited neurite outgrowth significantly. Anti-
BDNFAb inhibited neurite outgrowth too, but this effect was
lower than that of anti-NGF Ab (Figure 3(b)). Overall, the
results suggest that DHEA enhances neurite outgrowth by
regulating NGF and BDNF expression and release.
3.4. DHEA Induces Longer-Term Survival in Cultured Neu-
rons. The rat cortical neuron cultures treated with DHEA
maintained for one month in incubator refreshing the media
every 3 days. Extending DHEA treatment throughout the
30 d survival period increased the numbers of viable cells
(Figure 3(c)). One-way ANOVA followed by pairwise com-
parisons showed that DHEA by itself increased the number
of neuronal cells (presumed neurons) compared to controls
(no DHEA) (Figure 3(c)).
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Figure 2: Number of BrdU+ cells. Representative image showing BrdU+ cells in the brain cortex under DHEA treatment and using
antineurotrophins after DHEA treatment (a).Themajority of BrdU+ cells which survive in brain cortex ofWistar rats (b). In each experiment,
the data were obtained from nine animals.
4. Discussion
In this study, we provided evidences that DHEA increased
NGF and BDNF production, neuronal cell proliferation,
neuronal cell survival, and neurite outgrowth. The microen-
vironment of theCNS plays amajor role in controlling neuro-
genesis. Levels of neurosteroids in the blood and/or CNS are a
significant determinant in the formation of new neuronal
cells. Our results add a new point to this map: the neuros-
teroid DHEA promotes overexpression of NGF and BDNF.
DHEA is an important regulator for the proliferation of
neural stem cells [20–22]. First, we have determined the basal
levels of DHEA, NGF, BDNF, NT-3, and NT-4 molecules in
the brain cortex segments of Wistar rats (Figures 1(a) and
1(b)). DHEA (10−6mol/liter) administered to animals for 2
weeks increased the number of newly formed cells in the
brain cortex in samples that harvested 24 h (Figure 2(b)) after
the last injection of BrdU. In this time, we have the elevation
rate of NGF and BDNF production significantly observed
(Figure 1(b)) but there were no significant increase in NT-
3 and NT-4 levels (Figure 1(b)). The numbers of labeled
cells receiving DHEA and anti-NGF or anti-BDNF even was
smaller than that of controls (Figures 2(a) and 2(b)). The
cytotoxic effect of DHEA alone or with BDNF was not sig-
nificant in concentrations 10−6 or lower (data not presented
here).
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Figure 3: DHEA induced upregulation of NGF and BDNF facilitated the differentiation of rat cortical neurons. Neurons from the DHEA
treated rats were immunostained against neuronal marker MAP-2 (a). The number of neurite extending from each neuron is demonstrated.
Anti-NGF and anti-BDNF antibodies (1 𝜇g/mL) were used to block NGF and BDNF action fromDHEA treated groups (b). Effects of chronic
DHEA treatment on cell proliferation and survival via MTT assay (c). Data represent the mean ± S.D. In each experiment, the data were
obtained from nine animals.
We showed that DHEA in the absence of NGF and BDNF
did have a little effect on neurite outgrowth, but activation of
the cells by NGF and BDNF is necessary to the increase of
neuronal specific biomarkers (Figure 3(a)) and neurite out-
growth and expression (Figure 3(b)).
Despite the Ziegler results that showed that DHEA
decreases NGF-induced cell survival and shifts the cells
toward a neuroendocrine phenotype [23], our results showed
the increasing survival rate of DHEA treated cells in the con-
centration that has no cytotoxic effect on brain cortex cells.
On the other hand the cell source in our experiment was
different from that of them.
Activation of cells by NGF and/or BDNF is necessary
for DHEA to mediate the neurite outgrowth (Figures 3(a)
and 3(b)). In a study by Compagnone and Mellon, they
have demonstrated that DHEA in low concentrations of
10−9mol/liter caused neurite outgrowth in primary cultures
of mouse embryonic neurons [6]. In this case, our results
confirm their experiment; evenwe have different culture con-
ditions and different cell type from that used by Compagnone
and Mellon.
The steroids amount in the blood or brain is sensitive to a
variety of external events or intrinsic processes. So, the steroid
dependent control is a significant determinant of variations
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in the differentiation or the formation of new cells. In 2000,
A˚berg et al. showed thatDHEAmay activate the expression of
growth factors like systemic IGF that are contributing in neu-
rogenesis [23]. Also Morales et al. demonstrated that DHEA
increases the plasma concentration of these factors [24] and
that decrease inDHEAplasma levels is associatedwith neural
cells degeneration [25]. Our data showed the dose dependent
activity of DHEA (data not shown).The higher concentration
(10−4mol or higher) was cytotoxic for our cells. On the
contrary, other groups showed that DHEA could protect neu-
rons from amino acid induced cytotoxicity [8]. So the effect
of DHEA varies between the different cells. Also our experi-
ments showed increase in MAP-2 expression after the treat-
ment with DHEA (Figure 3(a)). Administration of anti-NGF
and anti-BDNF antibodies shows that DHEA induces MAP-
2 in cells via the formation of NGF and BDNF. If the newly
formed cells underDHEA treatment resembled those formed
neurons under basal conditions, then our work suggests that
regenerative pharmacology could provide that they will
become part of the functional neural network.
The neurotrophins exert both long-term cell survival
effects and short-term effects on neuronal cells. It is con-
firmed that BDNF promotes long-term effects on neurons
[26]. Our results demonstrated the significant increase in sur-
vival time of DHEA treated neurons especially after 2 weeks
(Figure 3(c)). It appears thatNT-3 is regulated independent of
neuronal activity, but its secretion is dependent on hormonal
levels and on BDNF levels [27]. Our results showed insignifi-
cant changes inNT-3 andNT-4 secretion. According to Lind-
holm et al., NT-3 indirectly can also be affected by the BDNF
levels in the brain. So the DHEA has no direct effect on these
neurotrophins (NT-3 and NT-4).
In a study by Gubba et al., they showed that DHEA
(100 nM) upregulated NGF after 3 h, but not at other time
points (12, 24, or 48 h). Also they showed that DHEA had no
effect on the other neurotrophins in mixed primary cultures
[28]. Of course they used different concentrations of DHEA
and astrocytes in their study.
Another hypothesis that has an important part in our
conclusion is that DHEA could bind to the NGF and BDNF
receptors and in this way exert these effects. Lazaridis et al.
have shown that DHEA binds to the NGF receptor [29]. So it
is possible that BDNF could provide the receptors for DHEA
too. The decreased levels of NGF and BDNF are found to
decrease trkA receptor and a loss of cholinergic neurons [30].
The pharmacologically induced strengthening of the cholin-
ergic system may play a role in alleviating age-associated
dysfunctions.
5. Conclusion
DHEA stimulates NGF and BDNF neurotrophins overex-
pression and release. It enhances neuronal cell survival,
neuronal cell proliferation, and neurite outgrowth via these
neurotrophins. If our results could be generalized for human,
so formation of new cells in the brain via regenerative phar-
macology could be important in treating neurodegenerative
diseases such as Alzheimer and Parkinson.
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